FDA Approves Bayer's New Class of Drug to Treeat Adults with PAH First and Only Drug Approved in United States to Treat Two Forms of Pulmonary Hypertension Bayer HealthCare
announced on Wednesday that the United States Food and Drug Administration
(FDA) has approved Adempas® (riociguat) tablets for the treatment of adults
with pulmonary arterial hypertension (PAH) and adults with persistent/recurrent
chronic thromboembolic pulmonary hypertension (CTEPH) to improve exercise
capacity, improve WHO functional class, and delay clinical worsening. |
|
|